biologic

Lantus

insulin glargine

Loss of exclusivityApril 2012projected — 12-year biologic exclusivity estimate
CompanySanofi-Aventis U.S. LLC

Drug detail

Brand nameLantus
Active ingredientinsulin glargine
Strength1,000UNITS/10ML (100UNITS/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalApril 2000
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Lantus patent cliff — loss of exclusivity April 2012 | CliffBio